These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

407 related items for PubMed ID: 22995881

  • 1. Unrestricted use of 2 new-generation drug-eluting stents in patients with acute myocardial infarction: a propensity score-matched analysis.
    Chen KY, Rha SW, Wang L, Li YJ, Li GP, Poddar KL, Park JY, Choi CU, Park CG, Seo HS, Oh DJ, Jeong MH, Ahn YK, Hong TJ, Kim YJ, Hur SH, Seong IW, Chae JK, Cho MC, Bae JH, Choi DH, Jang YS, Chae IH, Kim CJ, Yoon JH, Chung WS, Seung KB, Park SJ, KAMIR Investigators.
    JACC Cardiovasc Interv; 2012 Sep; 5(9):936-45. PubMed ID: 22995881
    [Abstract] [Full Text] [Related]

  • 2. Everolimus-eluting Xience v/Promus versus zotarolimus-eluting resolute stents in patients with diabetes mellitus.
    Park KW, Lee JM, Kang SH, Ahn HS, Kang HJ, Koo BK, Rhew JY, Hwang SH, Lee SY, Kang TS, Kwak CH, Hong BK, Yu CW, Seong IW, Ahn T, Lee HC, Lim SW, Kim HS.
    JACC Cardiovasc Interv; 2014 May; 7(5):471-81. PubMed ID: 24852802
    [Abstract] [Full Text] [Related]

  • 3. Clinical outcomes of everolimus- and zotarolimus-eluting stents in patients with acute myocardial infarction for small coronary artery disease.
    Cho SC, Jeong MH, Kim W, Ahn Y, Hong YJ, Kim YJ, Kim CJ, Cho MC, Han KR, Kim HS, Korea Acute Myocardial Infarction Registry Investigators.
    J Cardiol; 2014 Jun; 63(6):409-17. PubMed ID: 24314902
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. One-year clinical outcomes of everolimus- versus sirolimus-eluting stents in patients with acute myocardial infarction.
    Chen KY, Rha SW, Wang L, Li YJ, Li GP, Choi CU, Park CG, Seo HS, Oh DJ, Jeong MH, Ahn YK, Hong TJ, Kim YJ, Chae SC, Hur SH, Seong IW, Chae JK, Cho MC, Bae JH, Choi DH, Jang YS, Chae IH, Kim HS, Kim CJ, Yoon JH, Ahn TH, Chung WS, Seung KB, Park SJ, Korea Acute Myocardial Infarction Registry Investigators.
    Int J Cardiol; 2014 Oct 20; 176(3):583-8. PubMed ID: 25305704
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Impact of lesion length and vessel size on clinical outcomes after percutaneous coronary intervention with everolimus- versus paclitaxel-eluting stents pooled analysis from the SPIRIT (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System) and COMPARE (Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice) Randomized Trials.
    Claessen BE, Smits PC, Kereiakes DJ, Parise H, Fahy M, Kedhi E, Serruys PW, Lansky AJ, Cristea E, Sudhir K, Sood P, Simonton CA, Stone GW.
    JACC Cardiovasc Interv; 2011 Nov 20; 4(11):1209-15. PubMed ID: 22115661
    [Abstract] [Full Text] [Related]

  • 8. Comparison of Resolute zotarolimus-eluting stents versus everolimus-eluting stents in patients with metabolic syndrome and acute myocardial infarction: propensity score-matched analysis.
    Ji MS, Jeong MH, Ahn YK, Kim SH, Kim YJ, Chae SC, Hong TJ, Seong IW, Chae JK, Kim CJ, Cho MC, Rha SW, Bae JH, Seung KB, Park SJ, Hur SH, Korea Acute Myocardial Infarction Registry Investigators.
    Int J Cardiol; 2015 Nov 15; 199():53-62. PubMed ID: 26186631
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. 1-Year Outcomes of Everolimus-Eluting Bioresorbable Scaffolds Versus Everolimus-Eluting Stents: A Propensity-Matched Comparison of the GHOST-EU and XIENCE V USA Registries.
    Tamburino C, Capranzano P, Gori T, Latib A, Lesiak M, Nef H, Caramanno G, Naber C, Mehilli J, Di Mario C, Sabaté M, Münzel T, Colombo A, Araszkiewicz A, Wiebe J, Geraci S, Jensen C, Mattesini A, Brugaletta S, Capodanno D.
    JACC Cardiovasc Interv; 2016 Mar 14; 9(5):440-9. PubMed ID: 26875648
    [Abstract] [Full Text] [Related]

  • 11. Everolimus-eluting stents and zotarolimus-eluting stents for percutaneous coronary interventions: two-year outcomes in New York State.
    Hannan EL, Zhong Y, Wu C, Walford G, Holmes DR, Jacobs AK, Stamato NJ, Venditti FJ, Sharma S, Fergus I, King SB.
    Catheter Cardiovasc Interv; 2013 Jun 01; 81(7):1097-105. PubMed ID: 22707353
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Comparisons of everolimus and Paclitaxel-eluting stents in patients with acute myocardial infarction.
    Chen KY, Rha SW, Li YJ, Li GP, Oh DJ, Jeong MH, Kim YJ, Hur SH, Bae JH, Ahn TH, Korea Acute Myocardial Infarction Registry Investigators.
    J Interv Cardiol; 2015 Apr 01; 28(2):147-56. PubMed ID: 25884898
    [Abstract] [Full Text] [Related]

  • 16. Outcomes after unrestricted use of everolimus-eluting and sirolimus-eluting stents in routine clinical practice: a multicenter, prospective cohort study.
    Park DW, Kim YH, Song HG, Ahn JM, Kim WJ, Lee JY, Kang SJ, Lee SW, Lee CW, Park SW, Yun SC, Her SH, Hur SH, Park JS, Kim MK, Choi YS, Kim HS, Cho JH, Lee SG, Park YW, Jeong MH, Lee BK, Lee NH, Lim DS, Yoon J, Seung KB, Shin WY, Rha SW, Kim KS, Tahk SJ, Park BE, Ahn T, Yang JY, Jeong YS, Rhew JH, Park SJ, IRIS-DES Investigators.
    Circ Cardiovasc Interv; 2012 Jun 01; 5(3):365-71. PubMed ID: 22693347
    [Abstract] [Full Text] [Related]

  • 17. Second-generation everolimus-eluting stents versus first-generation sirolimus-eluting stents in acute myocardial infarction. 1-year results of the randomized XAMI (XienceV Stent vs. Cypher Stent in Primary PCI for Acute Myocardial Infarction) trial.
    Hofma SH, Brouwer J, Velders MA, van't Hof AW, Smits PC, Queré M, de Vries CJ, van Boven AJ.
    J Am Coll Cardiol; 2012 Jul 31; 60(5):381-7. PubMed ID: 22835668
    [Abstract] [Full Text] [Related]

  • 18. Prediction of 1-year clinical outcomes using the SYNTAX score in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a substudy of the STRATEGY (Single High-Dose Bolus Tirofiban and Sirolimus-Eluting Stent Versus Abciximab and Bare-Metal Stent in Acute Myocardial Infarction) and MULTISTRATEGY (Multicenter Evaluation of Single High-Dose Bolus Tirofiban Versus Abciximab With Sirolimus-Eluting Stent or Bare-Metal Stent in Acute Myocardial Infarction Study) trials.
    Garg S, Sarno G, Serruys PW, Rodriguez AE, Bolognese L, Anselmi M, De Cesare N, Colangelo S, Moreno R, Gambetti S, Monti M, Bristot L, Bressers M, Garcia-Garcia HM, Parrinello G, Campo G, Valgimigli M, STRATEGY and MULTISTRATEGY Investigators.
    JACC Cardiovasc Interv; 2011 Jan 31; 4(1):66-75. PubMed ID: 21251631
    [Abstract] [Full Text] [Related]

  • 19. Three-year patient-related and stent-related outcomes of second-generation everolimus-eluting Xience V stents versus zotarolimus-eluting resolute stents in real-world practice (from the Multicenter Prospective EXCELLENT and RESOLUTE-Korea Registries).
    Lee JM, Park KW, Han JK, Yang HM, Kang HJ, Koo BK, Bae JW, Woo SI, Park JS, Jin DK, Jeon DW, Oh SK, Park JS, Kim DI, Hyon MS, Jeon HK, Lim DS, Kim MG, Rha SW, Her SH, Hwang JY, Kim S, Choi YJ, Kang JH, Moon KW, Jang Y, Kim HS.
    Am J Cardiol; 2014 Nov 01; 114(9):1329-38. PubMed ID: 25217457
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.